Login / Signup

Estimation of the latent therapeutic demand for immunoglobulin therapies in autoimmune neuropathies in the United States.

Albert FarrugiaMegha BansalIvan Marjanovic
Published in: Vox sanguinis (2021)
Together with previous work on the LTD for IG in immunodeficiencies, these results indicate that current IG usage reflects the estimated LTD for the main indications for IG in the United States The wide range of LTD found in all these studies emphasizes the need for more precise assessment of the underlying variables, particularly disease prevalence and dosage. Further studies on other indications such as secondary immunodeficiencies will augment these results and will assist in guiding demand planning for IG use and plasma collection in the United States and inform blood policy in other countries.
Keyphrases
  • case control
  • public health
  • healthcare
  • risk factors
  • drug induced